Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients
This study has been completed.
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:
National Institutes of Health Clinical Center (CC)
First received: December 24, 2005
Last updated: January 24, 2017
Last verified: June 25, 2009
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||June 25, 2009|
|Primary Completion Date:||June 25, 2009 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Casazza JP, Bowman KA, Adzaku S, Smith EC, Enama ME, Bailer RT, Price DA, Gostick E, Gordon IJ, Ambrozak DR, Nason MC, Roederer M, Andrews CA, Maldarelli FM, Wiegand A, Kearney MF, Persaud D, Ziemniak C, Gottardo R, Ledgerwood JE, Graham BS, Koup RA; VRC 101 Study Team.. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis. 2013 Jun 15;207(12):1829-40. doi: 10.1093/infdis/jit098.